Polylactide-glycoli acid and rapamycin coating intraocular lens prevent posterior capsular opacification in rabbit eyes

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 6, 2009, Pages 801-807

  Liu, Hongling ^a   Wu, Lan ^a   Fu, Shaoying ^a   Hou, Yongsheng ^a   Liu, Ping ^a   Cui, Hao ^a   Liu, Jingjing ^a   Xing, Lin ^a   Zhang, Xiaomei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Intraocular lens; Polylactide glycoli acid (PLGA); Posterior capsule opacification; Rapamycin

Indexed keywords

POLYGLACTIN; POLYMER; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CATARACT; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN VIVO STUDY; LENS EPITHELIUM; LENS IMPLANTATION; NONHUMAN; OPERATION DURATION; PHACOEMULSIFICATION; PRIORITY JOURNAL; RABBIT; SLIT LAMP; TREATMENT DURATION;

ANIMALS; AQUEOUS HUMOR; CATARACT; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COATED MATERIALS, BIOCOMPATIBLE; DRUG CARRIERS; EPITHELIAL CELLS; IMMUNOSUPPRESSIVE AGENTS; LACTIC ACID; LENS CAPSULE, CRYSTALLINE; LENS IMPLANTATION, INTRAOCULAR; LENSES, INTRAOCULAR; PHACOEMULSIFICATION; POLYGLYCOLIC ACID; POSTOPERATIVE COMPLICATIONS; RABBITS; SIROLIMUS;

EID: 67349092193     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-1007-0     Document Type: Article

References (35)

1. Stark WJ, Sommer A, Smith RE (1989) Changing trends in intraocular lens implantation. Arch Ophthalmol 107:1441-1444
2. Ohrloff C, Schalnus R, Rothe R, Spitznas M (1990) Role of the posterior capsule in the aqueous-vitreous barrier in aphakic and pseudophakic eyes. J Cataract Refract Surg 16:198-201
3. McDonnell PJ, Patel A, Green WR (1985) Comparison of intracapsular and extracapsular cataract surgery. Histopathologic study of eyes obtained postmortem. Ophthalmology 92:1208-1225
4. Schaumberg DA, Dana MR, Christen WG, Glynn RJ (1998) A systematic overview of the incidence of posterior capsule opacification. Ophthalmology 105:1213-1221. doi: 10.1016/S0161-6420(98)97023-3
5. Apple DJ, Solomon KD, Tetz MR, Assia EI, Holland EY, Legler UF, Sai JC, Castaneda VE, Hoggatt JP, Kostick AM (1992) Posterior capsule opacification. Surv Ophthalmol 37:73-116. doi: 10.1016/ 0039-6257(92)90073-3
6. Kappelhof JP, Vrensen GF (1992) The pathology of after-cataract. A minireview. Acta Ophthalmol Suppl 205:13-24
7. Gao X, Cai KL, Wu XL, Yang XL, Huo W (2006) Rapamycin inhibits the pathogenesis of posterior capsule opacification experimental study on rabbit. J Shandong Univ 6:634-637
8. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323. doi: 10.1056/NEJMoa035071
9. Yang P, Li S (1998) Uveitis. People's Medical Publishing House, Beijing
10. Hepsen IF, Bayramlar H, Gültek A, Özen S, Tilgen F, Evereklioglu C (1997) Caffeic acid phenethyl ester to inhibit posterior capsule opacification in rabbits. J Cataract Refract Surg 23:1572-1576
11. Cobo LM, Ohsawa E, Chandler D, Arguello R, George G (1984) Pathogenesis of capsular opacification after extracapsular cataract extraction. An animal model. Ophthalmology 91:857-863
12. Frezzotti R, Caporossi A (1990) Pathogenesis of posterior capsule opacification. I. Epidemiological and clinicostatistical data. J Cataract Refract Surg 16:347-352
13. Frezzotti R, Caporossi A, Mastrengelo D, Hadjistilianou T, Tosi P, Cintorino M, Minacci C (1990) Pathogenesis of posterior capsule opacification. II. Histopathological and in vitro culture findings. J Cataract Refract Surg 16:353-360
14. Green WR, McDonnell PJ (1985) Opacification of the posterior capsule. Trans Ophthalmol Soc U K 104:727-739
15. McDonnell PJ, Stark WJ, Green WR (1984) Posterior capsule opacification: a specular microscopic study. Ophthalmology 91:853-856
16. McDonnell PJ, Krause W, Glaser BM (1988) In vitro inhibition of lens epithelial cell proliferation and migration. Ophthalmic Surg 19:25-30
17. Hansen TJ, Tyndall R, Soll DB (1987) Methotrexate-anticollagen conjugate inhibits in vitro lens cell outgrowth. Invest Ophthalmol Vis Sci 28:1206-1209
18. Sehgal SN, Baker H, Vézina C (1975) Rapamycin (AY-22,989), A new antifungal antibiotic: II. Fermentation, isolation, and characterization. J Antibiot 28:727-732
19. Vézina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989). A new antifungal antibiotic: I. Toxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 28:721-726
20. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188-1193. doi: 10.1161/hc3601.093987
21. Gummert JF, Ikonen T, Morris RE (1999) Newer immunosuppressive drugs: A review. J Am Soc Nephrol 10:1366-1380
22. Marx SO, Jayaraman T, Go LO, Marks AR (1995) Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76:412-417
23. Zhao J, Cai KL (2007) Effects of rapamycin on regeneration of cultured rabbit lens epithelial cells. Chin J Optom Ophthalmol 9:37-39
24. Regar E, Sianos G, Serruys PW (2001) Stent development and local drug delivery. Br Med Bull 59:227-248. doi: 10.1093/bmb/59.1.227
25. Klingemann HG (1995) Update on immunosuppressive drugs (A report from the International Consensus Conference on Immunosuppressive Drugs). DN&P 8:303-309
26. Ohia EO, Mancino M, Kulkarni PS (1992) Effects of steroids and immunosuppressive drug on endotoxin-uveitis in rabbits. J Ocul Pharmacol 8:295-307
27. Nishi O, Nishi K, Imanishi M, Tada Y, Shirasawa E (1995) Effect of the cytokines on the prostaglandin E2 synthesis by lens epithelial cells of human cataracts. Br J Ophthalmol 79:934-938. doi: 10.1136/bjo.79.10.934
28. Roberge FG, Xu D, Chan CC, de Smet MD, Nussenblatt RB, Chen H (1993) Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr Eye Res 12:197-203. doi: 10.3109/02713689308999487
29. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J (2004) Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 10:964-972
30. Chan CC, Martin DF, Xu D, Roberge FG (1995) Side effects of rapamycin in the rat. J Ocul Pharmacol Ther 11:177-181
31. Buech G, Bertelmann E, Pleyer U, Siebenbrodt I, Borchert HH (2007) Formulation of sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther 23:292-303. doi: 10.1089/jop.2006.130
32. Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ogura Y (2002) Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits. Graefes Arch Clin Exp Ophthalmol 240:672-678. doi: 10.1007/s00417-002-0484-9
33. Nishi O, Nishi K, Yamada Y, Mizumoto Y (1995) Effect of indomethacin-coated posterior chamber intraocular lenses on postoperative inflammation and posterior capsule opacification. J Cataract Refract Surg 21:574-578
34. Kwon YS, Kim JC (2006) Inhibition of corneal neovascularization by rapamycin. Exp Mol Med 38:173-179
35. Shi W, Gao H, Xie L, Wang S (2006) Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci 47:3339-3344. doi: 10.1167/iovs.05-1425